GRTX common stock will be delisted and deregistered, leaving no public trading market. The CVRs are illiquid and cannot be sold.
Price Chart
Executive Summary
Galera Therapeutics completed its merger with Obsidian Therapeutics (formerly Gazelle Parent) on August 3, 2026, becoming a wholly owned subsidiary. Existing Galera stockholders received ~0.7019 shares of Parent common stock per share plus contingent value rights (CVRs), representing only ~1.2% of the combined company on a fully diluted basis. The common stock will be delisted from the OTCQB and its SEC registration terminated, eliminating public market liquidity.
Key Financial Metrics
Key Facts
- Galera stockholders received 0.7019 shares of Parent common stock per share, plus two types of CVRs (80% of Legacy Product net proceeds for 5 years; 95% of Supportive-Care Product net proceeds for 10 years).
- Galera securityholders owned approximately 1.2% of the combined company on a fully diluted basis post-merger.
- All prior directors and officers of Galera resigned; new officers from Obsidian were appointed.
- Galera will file a Form 15 to deregister its common stock under Section 12(g) of the Exchange Act, suspending reporting obligations.
- The CVRs are non-transferable, unregistered, and there is no assurance any payments will be made.
Financial Impact
Galera securityholders received 730,057 shares of Parent common stock, representing ~1.2% of the combined entity. The CVRs offer contingent payments of 80% of net proceeds from Legacy Product (tilarganine) for 5 years and 95% from Supportive-Care Product (GC4419/GC4711) for 10 years, but no payments are guaranteed.
Risk Factors
- CVR payments are entirely contingent on future product monetization and may never materialize.
- Delisting and deregistration remove all public market liquidity and reporting transparency.
- Galera stockholders now hold a tiny, non-controlling stake in a private company with no exit mechanism.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-331207 |
| Document: d170816dex32.htm | 0001193125-26-331207 |
| Document: d170816d8k.htm | 0001193125-26-331207 |
| Document: d170816dex31.htm | 0001193125-26-331207 |
| Document: 0001193125-26-331207-index-headers.html | 0001193125-26-331207 |
| Document: 0001193125-26-331207-index.html | 0001193125-26-331207 |
| Document: 0001193125-26-331207.txt | 0001193125-26-331207 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | EFFECT | — | awaiting T+20 | — | — |
Aug 4, 2026 11w ago | 15-12G | — | awaiting T+20 | — | — |
Aug 3, 2026 11w ago | 8-K | — | awaiting T+20 | — | — |
Jul 13, 2026 15w ago | 8-K | $16.39 | awaiting T+20 | — | — |
Jul 7, 2026 15w ago | 8-K | $17.80 | awaiting T+20 | — | — |
May 21, 2026 22w ago | 425 | $0.1000 $0.0910 | ▼ −9.00% | ▼ −7.58% | — |
May 19, 2026 22w ago | 8-K | $0.1010 $0.0857 | ▲ +15.15% | ▲ +15.89% | — |
Apr 22, 2026 26w ago | 425 | $20.00 $20.20 | ▲ +1.00% | ▼ −3.22% | — |
Apr 22, 2026 26w ago | 425 | $20.00 $20.20 | ▲ +1.00% | ▼ −3.22% | — |
Apr 14, 2026 27w ago | Press Release | $0.0790 $0.1000 | ▼ −26.58% | ▼ −20.29% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers